Drugs / 99mTc pertechnetate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04724538 | Oct 2020 → Feb 2021 | COVID-19, viral pneumonia | National Medical Research Radiological Centre of the Ministry of Health of Russia | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02514187 | Oct 2015 → Apr 2017 | hyperthyroidism | British Columbia Cancer Agency | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 99mTc-pertechnetate | “The purpose of this study is to evaluate technetium-99m (99mTc) pertechnetate produced by a cyclotron as a replacement for 99mTc pertechnetate obtained from a generator...” NCT02514187 ↗ |
| Modality | Diagnostic / imaging agent | “undergo imaging using both cyclotron-produced 99mTc and the current standard method used at the site for thyroid imaging” NCT02514187 ↗ |
| Route | Inhaled | “Inhalation of 99mTc-pertechnetate aerosol” NCT04724538 ↗ |